Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain

被引：0
|
作者：
Carole Dembek
Leigh Ann White
Jayson Quach
Andrea Szkurhan
Nazia Rashid
M. R. Blasco
机构：
[1] Avalere Health,
[2] Biogen Idec,undefined
[3] Dymaxium,undefined
[4] Hospital Universitario Puerta de Hierro,undefined
来源：
The European Journal of Health Economics | 2014年 / 15卷
关键词：
Multiple sclerosis; Cost-effectiveness; Disease-modifying therapies; Interferon-beta; I1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：353 / 362
页数：9
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF NEW THERAPIES FOR MULTIPLE SCLEROSIS IN SPAIN
    Boix, B.
    Figueras, M.
    Riera, M.
    VALUE IN HEALTH, 2015, 18 (07) : A757 - A757
  • [42] The clinical and cost impact of switching to fingolimod versus other first line injectable disease-modifying therapies in patients with relapsing multiple sclerosis
    Freedman, M. S.
    Duquette, P.
    Grand'Maison, F.
    Lee, L.
    Vorobeychik, G.
    Lara, N.
    Khurana, V
    Nakhaipour, H. R.
    Schecter, R.
    Haddad, P.
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (05) : 767 - 776
  • [43] Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States
    Chirikov, Viktor
    Ma, Ingrid
    Joshi, Namita
    Patel, Dipen
    Smith, Alden
    Giambrone, Cindy
    Cornelio, Noelle
    Hashemi, Lobat
    VALUE IN HEALTH, 2019, 22 (02) : 168 - 176
  • [44] Effects of Cohort Selection on the Results of Cost-Effectiveness Analysis of Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis
    Becker, Russell V., III
    Dembek, Carole
    JOURNAL OF MANAGED CARE PHARMACY, 2011, 17 (05): : 377 - 381
  • [45] Number needed to treat analysis comparing teriflunomide with injectable and oral disease-modifying therapies in relapsing multiple sclerosis
    Freedman, M. S.
    Miller, A. E.
    Thangavelu, K.
    Hass, S.
    Leist, T. P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 668 - 668
  • [46] Disease-modifying therapies for multiple sclerosis
    De Angelis, Floriana
    John, Nevin A.
    Brownlee, Wallace J.
    BMJ-BRITISH MEDICAL JOURNAL, 2018, 363
  • [47] Multiple sclerosis and disease-modifying therapies
    Minen, Mia T.
    Karceski, Steven
    NEUROLOGY, 2011, 77 (04) : E26 - E26
  • [48] Real-world Effectiveness Of Initial Treatment With Newer Versus Injectable Disease-modifying Therapies In Pediatric Multiple Sclerosis
    Krysko, K. M.
    Graves, J. S.
    Rensel, M.
    Weinstock-Guttman, B.
    Rutatangwa, A.
    Aaen, G.
    Anita, B.
    Benson, L.
    Chitnis, T.
    Gorman, M.
    Goyal, M. S.
    Harris, Y.
    Krupp, L.
    Lotze, T.
    Mar, S.
    Moodley, M.
    Ness, J.
    Rodriguez, M.
    Rose, J.
    Schreiner, T.
    Tillema, J.
    Waltz, M.
    Casper, T.
    Waubant, E.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 46 - 47
  • [49] Real-world Effectiveness of Initial Treatment with Newer versus Injectable Disease-modifying Therapies in Pediatric Multiple Sclerosis
    Krysko, Kristen
    Graves, Jennifer
    Rensel, Mary
    Weinstock-Guttman, Bianca
    Rutatangwa, Alice
    Aaen, Gregory
    Belman, Anita
    Benson, Leslie
    Chitnis, Tanuja
    Gorman, Mark
    Goyal, Manu
    Harris, Yolanda
    Krupp, Lauren
    Lotze, Timothy
    Mar, Soe
    Moodley, Manikum
    Ness, Jayne
    Rodriguez, Moses
    Rose, John
    Schreiner, Teri
    Tillema, Jan-Mendelt
    Waltz, Michael
    Casper, T. Charles
    Waubant, Emmanuelle
    NEUROLOGY, 2020, 94 (15)
  • [50] Disease-modifying therapies for multiple sclerosis
    John R. Corboy
    Douglas S. Goodin
    Elliot M. Frohman
    Current Treatment Options in Neurology, 2003, 5 (1) : 35 - 54
12345